Sodium Pertechnetate Tc 99m use while Breastfeeding

Sodium Pertechnetate Tc 99m Levels and Effects while Breastfeeding

Summary of Use during Lactation

Information in this record refers to the use of sodium pertechnetate Tc 99m as a diagnostic agent. The United States Nuclear Regulatory Commission states that breastfeeding should be interrupted temporarily after administration of sodium pertechnetate Tc 99m to a nursing mother. The duration of breastfeeding interruption depends on the dose administered (see table). During the period of interruption, the breasts should be emptied regularly and completely. If the mother has expressed and saved milk prior to the examination, she can feed it to the infant during the period of nursing interruption.[1][2][3] The milk that is pumped by the mother during the time of breastfeeding interruption can either be discarded or stored refrigerated frozen and given to the infant after 10 physical half-lives, or about 60 hours, have elapsed. Mothers need not refrain from close contact with their infants after usual clinical doses.[4]

Mothers concerned about the level of radioactivity in their milk could ask to have it tested at a nuclear medicine facility at their hospital. When the radioactivity is at a safe level she may resume breastfeeding. A method for measuring milk radioactivity and determining the time when a mother can safely resume breastfeeding has been published.[5]

Dose Duration of Interruption
1100 MBq (30 mCi) 24 hours[6]
440 MBq (12 mCi) 12 hours[6]
185 MBq (5 mCi) 4 hours[5]

Drug Levels

Technetium 99m is a gamma emitter with a principal photon energy of 140.5 keV and a physical half-life of 6.024 hours.[6] The effective half-life of sodium pertechnetate Tc 99m averages 3.6 hours (range 2.8 to 5.5 hours).[1][5]

Effects in Breastfed Infants

Relevant published information was not found as of the revision date.

Effects on Lactation and Breastmilk

Relevant published information was not found as of the revision date.

References

1. Mountford PJ, Coakley AJ. A review of the secretion of radioactivity in human breast milk: data, quantitative analysis and recommendations. Nucl Med Commun. 1989;10:15-27. PMID: 2645546

2. Early PJ, Sodee DB. Principles and practice of nuclear medicine. 2nd ed. St. Louis. Mosby-Year Book, Inc. 1995:1380-1.

3. Administration of Radioactive Substances Advisory Committee. Notes for guidance on the clinical administration of radiopharmaceuticals and use of sealed radioactive sources. 2006;25-7. http://www.arsac.org.uk

4. Mountford PJ, O'Doherty MJ . Exposure of critical groups to nuclear medicine patients. Appl Radiat Isot. 1999;50:89-111. PMID: 10028630

5. Stabin MG, Breitz HB. Breast milk excretion of radiopharmaceuticals: mechanisms, findings, and radiation dosimetry. J Nucl Med. 2000;41:863-73. PMID: 10809203

6. Howe DB, Beardsley M, Bakhsh S. Appendix U. Model procedure for release of patients or human research subjects administered radioactive materials. In, NUREG-1556. Consolidated guidance about materials licenses. Program-specific guidance about medical use licenses. Final report. U.S. Nuclear Regulatory Commission Office of Nuclear Material Safety and Safeguards. 2008;9, Rev. 2. http://www.nrc.gov/reading-rm/doc-collections/nuregs/staff/sr1556/v9/r2/

Sodium Pertechnetate Tc 99m Identification

Substance Name

Sodium Pertechnetate Tc 99m

CAS Registry Number

23288-60-0

Drug Class

Radiopharmaceuticals

Technetium Compounds

Administrative Information

LactMed Record Number

685

Last Revision Date

20141107

Disclaimer

Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.

Disclaimer: This information is not intended as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. Use of this website signifies your agreement to the Terms of Use and Online Privacy Policy.

Hide
(web1)